Claims for Patent: 9,352,013

Summary for Patent: 9,352,013

Title:	Uses of bremelanotide in therapy for female sexual dysfunction
Abstract:	Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
Inventor(s):	Spana; Carl (West Harrison, NY), Jordan; Robert (Hamilton, NJ), Edelson; Jeffrey D. (Berwyn, PA)
Assignee:	Palatin Technologies, Inc. (Cranbury, NJ)
Application Number:	14/313,258
Patent Claims:	1. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction and anticipating sexual activity, while reducing side effects associated with the administration of bremelanotide, comprising administering to the female patient by subcutaneous injection an aqueous solution comprising acetate salt of bremelanotide between 6% and 12% (w/w) acetic acid, and 2.5% glycerin (w/v), in an amount sufficient to result in a peak plasma concentration of bremelanotide within 60 minutes after administration of bremelanotide in the female patient of no more than 120 ng/mL, thereby treating female sexual dysfunction while reducing undesirable side effects. 2. The method of claim 1, wherein the peak plasma concentration is no more than 100 ng/mL. 3. The method of claim 1, wherein the side effects comprise one or more of nausea, flushing, headache, changes in systolic blood pressure, changes in diastolic blood pressure, changes in heart rate, vomiting, and hypertension. 4. The method of claim 1, wherein between 1.25 and 1.75 mg of net bremelanotide added as the acetate salt is administered. 5. The method of claim 1, wherein the aqueous solution consists of bremelanotide added as the acetate salt in an excess of acetic acid, 2.5% glycerin (w/v), water and optionally one or more agents to adjust pH. 6. The method of claim 5, wherein between 6% and 12% (w/w) acetic acid is in the aqueous solution of bremelanotide. 7. The method of claim 1, wherein the aqueous solution is at a pH of 5.0, and further comprises one or more agents to adjust pH. 8. The method of claim 7, wherein the one or more agents to adjust pH are selected from the group consisting of hydrochloric acid and sodium hydroxide. 9. The method of claim 1, wherein the female patient is premenopausal. 10. The method of claim 1, wherein the variability in peak plasma concentration within 60 minutes after subcutaneous injection is a percent coefficient of variation (% CV) less than 30. 11. The method of claim 1, wherein the variability in peak plasma concentration within 60 minutes after subcutaneous injection of the aqueous solution is less than the variability in peak plasma concentration within 60 minutes after intranasal administration of an equivalent dosage of bremelanotide or a pharmaceutically acceptable salt of bremelanotide. 12. The method of claim 11, wherein the variability in peak plasma concentration within 60 minutes after subcutaneous injection is a % CV less than 30. 13. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction and anticipating sexual activity, while reducing side effects associated with the administration of bremelanotide, comprising administering to the female patient by subcutaneous injection a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide and 2.5% glycerin (w/v) in an amount sufficient to result in a peak plasma concentration of bremelanotide within 60 minutes after administration of bremelanotide in the female patient of no more than 120 ng/mL, thereby treating female sexual dysfunction while reducing undesirable side effects. 14. The method of claim 13, wherein the peak plasma concentration is no more than 100 ng/mL. 15. The method of claim 13, wherein between 1.25 and 1.75 mg of net bremelanotide is administered. 16. The method of claim 13, wherein the side effects comprise one or more of nausea, flushing, headache, changes in systolic blood pressure, changes in diastolic blood pressure, changes in heart rate, vomiting, and hypertension. 17. The method of claim 13, wherein the composition is an aqueous solution consisting of bremelanotide added as the acetate salt in an excess of acetic acid, optionally one or more agents to adjust pH, water and 2.5% glycerin (w/v). 18. The method of claim 17, wherein between 6% and 12% (w/w) acetic acid is in the aqueous solution of bremelanotide. 19. The method of claim 13, wherein the composition is at a pH of 5.0, and further comprises one or more agents to adjust pH. 20. The method of claim 19, wherein the one or more agents to adjust pH are selected from the group consisting of hydrochloric acid and sodium hydroxide. 21. The method of claim 13, wherein the female patient is premenopausal. 22. The method of claim 13, wherein the variability in peak plasma concentration within 60 minutes after subcutaneous injection is a percent coefficient of variation (% CV) less than 30. 23. The method of claim 13, wherein the variability in peak plasma concentration within 60 minutes after subcutaneous injection of the composition is less than the variability in peak plasma concentration within 60 minutes after intranasal administration of an equivalent dosage of bremelanotide or a pharmaceutically acceptable salt of bremelanotide. 24. The method of claim 23, wherein the variability in peak plasma concentration within 60 minutes after subcutaneous injection is a % CV less than 30.